Cellectis S.A. (CLLS)

Market Cap	352.17M
Revenue (ttm)	82.55M
Net Income (ttm)	-35.35M
Shares Out	72.33M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,165
Open	5.040
Previous Close	4.750
Day's Range	4.815 - 5.100
52-Week Range	1.100 - 5.480
Beta	3.04
Analysts	Strong Buy
Price Target	8.50 (+71.37%)
Earnings Date	Nov 7, 2025

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2007
• Employees: 222
• Stock Exchange: NASDAQ
• Ticker Symbol: CLLS
• Website: https://www.cellectis.com

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CLLS stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 71.37% from the latest price.

Price Target

$8.5

(71.37% upside)

Analyst Consensus: Strong Buy